|Bid||0.000 x 2900|
|Ask||0.000 x 1200|
|Day's Range||0.211 - 0.219|
|52 Week Range||0.150 - 0.650|
|Beta (3Y Monthly)||0.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2017 - May 19, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.52|
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in combination with checkpoint inhibitors (CPIs). The Phase IIa clinical trial will evaluate the immune-mediated effects of cytokine modulation in combination with CPIs in patients with primary resistance to CPI therapy. The protocol will seek to evaluate the combination of Ampligen and CPIs in patients with advanced urothelial carcinoma, renal cell carcinoma and melanoma.
Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen® (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS expanded access program (EAP) in the United States and Europe and an EAP in the Netherlands for pancreatic cancer. Ampligen, a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, was approved for commercial sale in Argentina in 2016 for the treatment of ME/CFS, the first therapy ever approved for this quality-of-life impacting disease.
Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released for patients' use in the pancreatic cancer Early Access Program (EAP) in the Netherlands pursuant to the terms of our agreement with our EAP provider. This is the initial shipment (500 vials) of a previously announced 2,100 vial standing stock order issued by myTomorrows, our EAP provider in Europe (https://globenewswire.com/news-release/2016/05/23/842404/0/en/Hemispherx-Amends-and-Restates-Agreement-with-myTomorrows-for-the-Early-Access-Program-for-Rintatolimod-in-Europe.html; https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/form10-k.htm). Early Access Programs, also known as Expanded Access Programs, are market-specific regulatory programs whereby certain governments allow companies to make a drug available with reimbursement approved before it is officially commercialized for serious or life-threatening diseases outside of a clinical trial — if certain criteria are met — with potential benefits both for patients and for drug development.
ORLANDO, Fla., Aug. 24, 2018-- Hemispherx Biopharma, Inc. an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it will be presenting ...
Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, has announced its financial results for the six months ended June 30, 2018. The Company has made great progress pursuing Ampligen in combination therapeutic treatments in immuno-oncology. Significant synergistic anti-tumor activity and/or increased median survival has been observed when Ampligen was added to other anti-cancer agents in three pre-clinical studies.
Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, is pleased to announce it mailed a letter to stockholders on August 11, 2018 detailing recent developments, including financial results and new business opportunities. A strategic decision to prioritize Ampligen’s potential in combination therapeutic treatments in immuno-oncology.
Stock Research Monitor: HEB, HTBX, and PBYI LONDON, UK / ACCESSWIRE / July 30, 2018/ If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . On Friday, benchmark US ...
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.
After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).